Pacer Advisors
IRLA

Pacer Advisors’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Pacer Advisors’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6
Closed -$45K – 1524
2021
Q1 		$45K Hold
6
– – ﹤0.01% 1450
2020
Q4 		$31K Buy
+6
New +$53.2K ﹤0.01% 1459

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $31.9B AUM 28.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Pacer Advisors's IRLA Position: Q2 2021 in Review

Pacer Advisors sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2021, closing a stake of 6 shares — an estimated $45K sold.

Pacer Advisors first reported a position in IRLA in Q4 2020 and held it in 2 quarters. The position peaked at $45K in Q1 2021. 100 funds tracked by Wall St. Rank hold IRLA as of Q2 2021.

  • Pacer Advisors reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Pacer Advisors sold 6 IRulya Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $45K.
  • Pacer Advisors first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Pacer Advisors's IRulya Therapeutics Inc. Common Stock position peaked at $45K in Q1 2021.
  • 100 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.